GLP-1 Is a Coronary Artery Vasodilator in Humans by Clarke, Sophie J. et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
GLP-1 Is a Coronary Artery Vasodilator in Humans
Clarke, Sophie J.; Giblett, Joel P.; Yang, Lucy L.; Hubsch, Annette; Zhao, Tian; Aetesam-ur-
Rahman, Muhammad; West, Nick E. J.; O'Sullivan, Michael; Figg, Nichola; Bennett, Martin;
Albrechtsen, Nicolai J. Wewer; Deacon, Carolyn F.; Cheriyan, Joseph; Hoole, Stephen P.
Published in:
Journal of the American Heart Association
DOI:
10.1161/JAHA.118.010321
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Citation for published version (APA):
Clarke, S. J., Giblett, J. P., Yang, L. L., Hubsch, A., Zhao, T., Aetesam-ur-Rahman, M., ... Hoole, S. P. (2018).
GLP-1 Is a Coronary Artery Vasodilator in Humans. Journal of the American Heart Association, 7(22),
[e010321]. https://doi.org/10.1161/JAHA.118.010321
Download date: 03. Feb. 2020
GLP-1 Is a Coronary Artery Vasodilator in Humans
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Muhammad Aetesam-ur-Rahman, BM, BS; Nick E. J. West, MD; Michael O’Sullivan, PhD; Nichola Figg, PhD; Martin Bennett, PhD;
Nicolai J. Wewer Albrechtsen, PhD; Carolyn F. Deacon, PhD; Joseph Cheriyan, PhD; Stephen P. Hoole, MA, DM
Background-—The mechanism underlying the beneﬁcial cardiovascular effects of the incretin GLP-1 (glucagon-like peptide 1) and
its analogues in humans is elusive. We hypothesized that activating receptors located on vascular smooth muscle cells to induce
either peripheral or coronary vasodilatation mediates the cardiovascular effect of GLP-1.
Methods and Results-—Ten stable patients with angina awaiting left anterior descending artery stenting underwent forearm
blood ﬂow measurement using forearm plethysmography and post–percutaneous coronary intervention coronary blood ﬂow
measurement using a pressure-ﬂow wire before and after peripheral GLP-1 administration. Coronary sinus and artery bloods
were sampled for GLP-1 levels. A further 11 control patients received saline rather than GLP-1 in the coronary blood ﬂow
protocol. GLP-1 receptor (GLP-1R) expression was assessed by immunohistochemistry using a speciﬁc GLP-1R monoclonal
antibody in human tissue to inform the physiological studies. There was no effect of GLP-1 on absolute forearm blood ﬂow or
forearm blood ﬂow ratio after GLP-1, systemic hemodynamics were not affected, and no binding of GLP-1R monoclonal
antibody was detected in vascular tissue. GLP-1 reduced resting coronary transit time (mean [SD], 0.87 [0.39] versus
0.63 [0.27] seconds; P=0.02) and basal microcirculatory resistance (mean [SD], 76.3 [37.9] versus 55.4 [30.4] mm Hg/s;
P=0.02), whereas in controls, there was an increase in transit time (mean [SD], 0.48 [0.24] versus 0.83 [0.41] seconds;
P<0.001) and basal microcirculatory resistance (mean [SD], 45.9 [34.7] versus 66.7 [37.2] mm Hg/s; P=0.02). GLP-1R
monoclonal antibody binding was conﬁrmed in ventricular tissue but not in vascular tissue, and transmyocardial GLP-1
extraction was observed.
Conclusions-—GLP-1 causes coronary microvascular dilation and increased ﬂow but does not inﬂuence peripheral tone. GLP-1R
immunohistochemistry suggests that GLP-1 coronary vasodilatation is indirectly mediated by ventricular-coronary cross talk.
( J Am Heart Assoc. 2018;7:e010321. DOI: 10.1161/JAHA.118.010321.)
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I schemic heart disease resulting from coronary arterydisease remains the leading cause of death globally. Type
2 diabetes mellitus is a signiﬁcant cardiovascular risk factor
and is becoming increasingly prevalent. Compared with the
general population, patients with type 2 diabetes mellitus
have a signiﬁcantly increased risk of atherosclerotic coronary
artery disease and myocardial infarction as well as a higher
risk of developing heart failure and associated mortality.1–4
The poor prognosis of patients with type 2 diabetes mellitus
is partially explained by the diffuse distribution of their
coronary artery disease, as well as metabolic dysfunction
that particularly affects the systemic microvasculature,
including the heart.1,2,5 Improving the microcirculatory
function in patients with type 2 diabetes mellitus could
reduce morbidity and improve prognosis after myocardial
infarction.6
Modulation of the GLP-1 (glucagon-like peptide 1)
pathway is beneﬁcial in the treatment of diabetes mellitus.
Studies assessing the incretin hormone GLP-1 receptor
(GLP-1R) agonists and dipeptidyl peptidase-4 (the enzyme
responsible for GLP-1 [7-36] breakdown to metabolically
inactive GLP-1 [9–36]) inhibitors, used to treat diabetes
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mellitus, have conﬁrmed that these classes of antihyper-
glycemic drugs do not appear to have deleterious cardio-
vascular effects,7–9 unlike other agents, and suggest that
these agents may actually be cardioprotective.10–14 There
are 2 studies to date, in which GLP-1R agonists liraglutide
and semaglutide were associated with a reduction in
myocardial infarction and cardiovascular death compared
with placebo.7,15 The mechanism behind these nonglycemic
effects is not clear, but the GLP-1R has been reported to be
expressed in vascular smooth muscle cells16,17; and active
GLP-1 (7–36) NH2 and its metabolite (9–36) NH2 are
thought to have peripheral vasodilatory effects in
animals.18–20 These vasodilatory effects may be beneﬁcial
cardioprotectively in patients with diabetes mellitus,
although supporting data in humans are not extensive or
consistent.21–25
We designed a mechanistic study to comprehensively
evaluate the effects of GLP-1 (7–36) on both coronary and
peripheral artery vascular tone in the same patients and to
determine whether GLP-1 extraction occurred by measuring
the transmyocardial gradient of GLP-1 (7–36) and GLP-1 (9–
36) during GLP-1 (7–36) administration. We also assessed the
pattern of GLP-1R expression by immunohistochemistry in
human tissue samples, to support our physiological study
ﬁndings.
Methods
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure, other than
what is presented in this article.
Forearm and Coronary Blood Flow Protocols
Twenty-one patients with stable angina and a stenosis to their
proximal left anterior descending coronary artery requiring
stenting were identiﬁed at the cardiology preadmission clinic
from the waiting list for elective percutaneous coronary
intervention (PCI) at Royal Papworth Hospital between
December 2015 and August 2017.
Patients receiving GLP-1–based therapy (GLP-1R agonist or
dipeptidyl peptidase-4 inhibitor) were excluded to ensure
baseline levels of GLP-1 were in the physiological range.
Patients receiving insulin were also excluded to minimize the
risk of hypoglycemia; and those taking calcium channel
blockers, nicorandil, or oral nitrates had them discontinued
48 hours before assessment, because of the vasodilatory
effects of these medications. The ﬁrst 10 patients were
invited to participate in both the forearm and coronary blood
ﬂow studies to assess the effect of GLP-1. A further 11
patients were block allocated as saline control patients in the
coronary blood ﬂow protocol.
The protocol was approved by the local ethics committee
(Health Research Authority (HRA) Committee East of England,
Research Ethics Committee (REC) reference 14/EE/0018),
and written informed consent was obtained from all partic-
ipants before they were enrolled into the study. The study
was performed according to institutional guidelines, was
registered on http://www.clinicaltrials.gov (unique identiﬁer:
NCT03502083), and was performed in accordance with the
Declaration of Helsinki.
Forearm Blood Flow Study
All procedures were performed in a quiet and temperature-
controlled room (232°C). Subjects were asked to refrain
from alcohol, caffeinated beverages, and any vigorous exer-
cise for 24 hours before the forearm blood ﬂow study. The
volunteers were encouraged to stay as still as possible
throughout the forearm blood ﬂow study.
A 27-gauge needle (Coopers Needleworks, Birmingham,
UK) was inserted into the brachial artery, usually in the
nondominant arm, under local anesthesia (1% lignocaine
hydrochloride; Hameln Pharmaceuticals Ltd). Venous occlud-
ing cuffs on both the upper arms were inﬂated to 40 to
45 mm Hg for 5 to 10 seconds to interrupt the venous ﬂow,
and arteriovenous communications in both the hands were
removed by inﬂating the wrist cuffs to above systolic pressure
(200–220 mm Hg). Basal and stimulated (after GLP-1) fore-
arm blood ﬂow responses were measured by mercury strain
gauges, which act as resistors, placed at the widest part of
both the forearms.26
Basal blood ﬂow was measured after 15 minutes of saline
infusion. A ﬁnger-prick blood glucose test result was
measured at the start, and after each dose of GLP-1, if it
Clinical Perspective
What Is New?
• We demonstrate that the incretin hormone GLP-1 (gluca-
gon-like peptide 1) does not have an effect on peripheral
vasculature tone in humans but is a coronary vasodilator
and reduces coronary microcirculatory resistance.
• GLP-1 myocardial extraction is observed, but GLP-1 recep-
tor expression is not found, on human vasculature, although
it is expressed on left ventricular tissue.
• GLP-1 does not appear to signiﬁcantly alter the availability
of myocardial substrate.
What Are the Clinical Implications?
• GLP-1 may exert its cardioprotective effect, which is
independent of glycemic control, by reducing coronary
microcirculatory resistance and improving myocardial blood
ﬂow.
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was <3 mmol/L at any point, the study was terminated. Five
weight-adjusted concentrations of GLP-1 (0.0375, 0.075,
0.15, 0.3, and 0.6 pmol/kg per minute) were then infused at
a rate of 1 mL/min intra-arterially by an infusion pump (Alaris
GH; Cardinal Health, Switzerland), each for 6 minutes; and
forearm blood ﬂow was measured during the last 3 minutes of
each dose. Blood pressure in the noninfused arm was
recorded by automated cuff at baseline, and after each dose
of GLP-1, and heart rate was recorded by Electrocardiogram
monitor at baseline and every minute during the GLP-1
infusions. GLP-1 was washed out with saline at the end of the
study before removing the arterial needle. Patients were
allowed to eat and drink, and their blood glucose was
monitored for 2 hours before they were discharged.
Forearm blood ﬂow data were analyzed using LabChart 8
(ADInstruments, Oxford, UK). The ﬁnal 5 good-quality traces,
usually recorded in the last minute of each 3-minute
recording, were analyzed; and they were expressed as mean
forearm blood ﬂow in milliliters per minute per 100 mL
forearm tissue, in the infused arm only, or as a ratio between
infused and noninfused arm.27
Coronary Blood Flow Study
PCI was performed via radial or femoral arterial approach
using 6F guide catheters. A 6F femoral venous sheath was
inserted for central venous administration of adenosine and
peripheral blood sampling. A multipurpose or Amplatz left
catheter was positioned from the venous sheath into the right
atrium for assessment of central venous pressure (Pv) and
blood sampling from the coronary sinus. The coronary guide
catheter provided access for coronary artery blood sampling.
Figure 1. Representative screen shots of pressure wire–derived indexes measured in the same patient at
baseline (top panel) after percutaneous coronary intervention and after a 20-minute infusion of GLP-1
(glucagonlike peptide-1; bottom panel). After GLP-1, the mean resting transit time (Tmn; blue thermodilution
curves) shortens from 0.67 to 0.36 seconds because of increased resting ﬂow velocity, and this reduces
calculated basal microcirculatory resistance (BMR). CFR indicates coronary ﬂow reserve; FFR, fractional
ﬂow reserve; IMR, index of microcirculatory resistance; Pa, aortic pressure; Pd, coronary distal pressure.
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All patients received aspirin, 300 mg, and clopidogrel,
300 mg, preloading. Patients were anticoagulated with a
heparin bolus (70–100 U/kg) after arterial sheath insertion to
achieve an activated clotting time >250 seconds. Iopromide
(Ultravist; Bayer HealthCare Pharmaceuticals, Leverkusen,
Germany) was used as the contrast agent for all cases. The
choice of stent and implantation technique was left to
operator discretion.
Pressure Wire Assessment
After proximal left anterior descending artery PCI, a Pres-
sureWire X (Abbott, Santa Clara, CA), linked wirelessly to
Coroventis analysis software, was calibrated to atmospheric
pressure before insertion and then advanced to the tip of the
guiding catheter, where aortic and wire pressures were
equalized. The wire was then advanced distally in the stented
left anterior descending artery, with the pressure transducer
positioned in the distal third of the coronary artery in a
segment free from adjacent side branches; and this position
was maintained throughout the study. A 0.2-mg bolus of
intracoronary glyceryl trinitrate was administered, and once
steady state was achieved, baseline coronary pressure and
ﬂow measurements were measured. The latter was derived
from the reciprocal of transit time (Tmn) of an intracoronary
injectate of room-temperature saline (thermodilution tech-
nique), as previously described.28–30 Coronary microcircula-
tory hyperemia was induced by intravenous administration of
adenosine, 0.14 mg/kg per minute, into the femoral vein. At
maximal hyperemia, Tmn, aortic pressure (Pa), and coronary
distal pressure (Pd) were recorded (Figure 1). Coronary wedge
pressure (Pw) was measured separately as Pd during occlusive
balloon inﬂation within the stented segment. Measurements
were recorded at baseline after stent deployment and after a
20-minute infusion of GLP-1 (7–36) via peripheral vein at a
dose of 1.2 pmol/kg per minute (n=10) or an infusion of
normal saline (control group, n=11) determined by block
allocation. At the end of the procedure, the pressure wire was
withdrawn to the coronary ostium to enable pressure-drift
correction of Pd as necessary.
Table 1. Patient Demographics
Demographics
GLP-1 Group
(n=10)
Control Group
(n=11) P Value
Age, y 68.3 (10.0) 61.8 (7.2) 0.11
Male sex 8 (80) 11 (100) 0.21
Weight, kg 88.4 (15.3) 91.2 (11.6) 0.63
Height, m 1.71 (0.15) 1.76 (0.07) 0.33
Body mass index, kg/m2 30.2 (3.0) 29.7 (5.2) 0.79
Comorbidity
Pre–diabetes mellitus 1 (10) 2 (18) 1.00
Hypertension 6 (60) 8 (73) 0.66
Previous MI 1 (10) 8 (73) <0.01
(Ex-) smoker 7 (70) 7 (64) 1.00
Medications
ACEI/ARB 3 (30) 7 (64) 0.20
Statin 10 (100) 11 (100) 1.00
b-Blocker 4 (40) 8 (73) 0.20
Blood
Total cholesterol,
mg/dL
178.7 (95.4) 160.7 (14.5) 0.54
Creatinine, mg/dL 1.0 (0.2) 1.0 (0.2) 0.58
Intervention
Stent length, mm 36.7 (14.8) 36.5 (17.1) 0.97
Stent diameter, mm 3.4 (0.6) 3.6 (0.5) 0.34
Total balloon
inflation time, s
107.5 (39.8) 119.2 (56.8) 0.60
Data are given as mean (SD) or number (percentage). ACEI indicates angiotensin-
converting enzyme inhibitor; ARB, angiotensin II receptor blocker; GLP-1, glucagon-like
peptide-1; MI, myocardial infarction.
Figure 2. No signiﬁcant change in heart rate from baseline and every minute during the 6 infused doses
of GLP-1 (glucagon-like peptide-1 [7–36]): 0.0375, 0.075, 0.15, 0.3, and 0.6 pmol/kg per minute; n=10.
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These measurements enabled the calculation of the
following: index of microcirculatory resistance (mm Hg/s or
units)=Pa9Tmn9[(PdPw)/(PaPw)]hyperemia corrected for col-
laterals12; basal microcirculatory resistance (BMR; mm Hg/s
or units)=Pa9Tmn9 [(PdPw)/(PaPw)]baseline; resistance
reserve ratio=BMR/index of microcirculatory resistance;
coronary ﬂow reserve (CFR)=Tmn(baseline)/Tmn(hyperemia); and
fractional ﬂow reserve=(PdPv)/(PaPv)hyperemia.
Blood glucose was measured at baseline and again after
the 20-minute infusion of GLP-1 to monitor and respond to
any hypoglycemia. Heart rate and blood pressure were also
recorded at baseline and after the 20-minute GLP-1
infusion. Once all measures had been collected, the GLP-
1 infusion was terminated and patients resumed their usual
clinical care.
Biochemistry
Paired blood samples were taken simultaneously from the
coronary sinus, coronary artery, and peripheral vein at the end
of the stent procedure and during the last minute of GLP-1 (7–
36) infusion to measure GLP-1 (7–36), GLP-1 (9–36), insulin,
free fatty acids, glucose, and lactate. Syringes for GLP-1
samples were preﬁlled with dipeptidyl peptidase-4 inhibitor
(Millipore, UK) to prevent degradation. Intact GLP-1 (7–36)
NH2 and the GLP-1 metabolite (9–36) NH2 were measured
using a speciﬁc sandwich ELISA, as described previously.31,32
Immunohistochemistry
Finally, human tissue from anonymous donors, provided by
the Royal Papworth Hospital Tissue Bank and the Cambridge
Biorepository for Translational Medicine (http://www.cb
tm.group.cam.ac.uk), was analyzed by immunohistochemistry
to help us correlate our clinical ﬁndings with GLP-1R
localization.
Figure 3. No change from baseline in systolic (A) or diastolic (B)
blood pressure during the 6 infused doses of glucagon-like
peptide-1 (GLP-1 [7–36]) over 30 minutes; n=10.
Figure 4. A, Absolute change in forearm blood ﬂow did not
change signiﬁcantly in either the control (P=0.17) or infused
(P=0.77) arms. B, Percentage change in forearm blood ﬂow ratio
between the control and infused arms was also not different
(P=0.20); n=10. GLP-1 indicates glucagon-like peptide-1.
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Tissue samples were ﬁxed in 4% paraformaldehyde in
0.1 mol/L phosphate buffer for a minimum of 24 hours
before dehydration and parafﬁn embedding. Pancreas was
used as a positive control and stained with hematoxylin-
eosin to identify the b cells. Tissue samples from pancreas,
atria, ventricle, coronary artery, saphenous vein, left internal
mammary artery, radial artery, and aorta underwent
immunohistochemistry analysis using the monoclonal anti-
body (mAb) 3F52 GLP-1R antibody; this antibody was
sourced from the University of Iowa Developmental Studies
Hybridoma Bank and labelled with 3,30-diaminobenzidine,
which is oxidized in the presence of peroxidase and
hydrogen peroxide, depositing a brown, alcohol-insoluble
precipitate at the site of enzymatic activity.17 mAb 3F52
was deposited to the Developmental Studies Hybridoma
Bank by L.B. Knudsen (Developmental Studies Hybridoma
Bank Hybridoma Product mAb 3F52) and has previously
been validated as speciﬁc for the GLP-1R, to map GLP-1R
expression.17
Power Calculation and Statistical Analysis
In the coronary blood ﬂow study, patients acted as their own
control, and the primary end point for the study was change in
BMR. On the basis of previous data, we calculated that 10
paired data sets would provide 80% power to detect a
clinically signiﬁcant difference (DBMR, 20 mm Hg.s; SD,
15 mm Hg.s) after administration of GLP-1.
Statistical analyses were performed in GraphPad Prism,
Version 6 (GraphPad Software, CA). Continuous data are
presented as means (SDs) and were analyzed by paired
(serial measures in the same patient) and unpaired
(between patient groups) Student t test or Wilcoxon rank,
as appropriate. Categorical data are presented as counts or
frequencies (percentages) and were analyzed by v2 or
Fisher’s exact test, as appropriate. In the forearm blood
ﬂow study, forearm blood ﬂow at varying GLP-1 doses was
compared using a 1-way repeated-measures ANOVA model.
All calculations were 2 tailed, and P<0.05 was deemed
statistically signiﬁcant.
Results
Demographics for patients who received GLP-1 in the forearm
and underwent PCI blood ﬂow studies and for control patients
in the PCI blood ﬂow study are summarized in Table 1. The
groups were well matched in terms of baseline demographics,
medical history, and medications. There were signiﬁcantly
more patients with a previous myocardial infarction in the
Table 2. Coronary Blood Flow Results at Baseline and After GLP-1 or Saline Administration for 20 Minutes
Variable Treated Baseline
Treated 20 Minutes
After GLP-1 P Value Control Baseline
Control
20 Minutes After Stent P Value
Heart rate, bpm 63.7 (7.3) 63.0 (13.8) 0.85 79.3 (32.1) 68.7 (11.9) 0.35
Systolic BP, mm Hg 136.3 (28.8) 138.3 (22.3) 0.59 133.1 (36.0) 140.0 (26.1) 0.46
Diastolic BP, mm Hg 59.6 (6.5) 63.4 (7.7) 0.08 72.3 (17.1) 71.8 (15.3) 0.68
Nonhyperemic
Pa, mm Hg 89.7 (16.5) 90.8 (16.6) 0.66 97.4 (23.3) 89.5 (15.3) 0.13
Pd, mm Hg 84.6 (16.5) 84.9 (15.9) 0.92 93.3 (24.1) 86.3 (16.7) 0.17
Tmn, s 0.87 (0.39)* 0.63 (0.27) 0.02* 0.48 (0.24)* 0.83 (0.41) <0.001*
BMR 76.3 (37.9) 55.4 (30.4) 0.02* 45.9 (34.7) 66.7 (37.2) 0.02*
Hyperemic
Pa, mm Hg 81.2 (17.8) 80.1 (16.7) 0.61 90.6 (19.9) 84.9 (18.3) 0.11
Pd, mm Hg 71.9 (14.9) 71.9 (15.3) 1.00 81.6 (19.7) 76.2 (17.1) 0.14
Tmn, s 0.24 (0.10) 0.29 (0.22) 0.55 0.20 (0.07) 0.21 (0.07) 0.87
IMR 16.3 (10.2) 19.7 (14.6) 0.52 15.6 (5.8) 15.0 (6.2) 0.78
FFR 0.88 (0.06) 0.89 (0.06) 0.49 0.89 (0.08) 0.89 (0.08) 0.76
CFR 4.0 (2.2) 3.0 (2.4) 0.36 2.4 (0.8) 4.2 (2.0) <0.01*
RRR 5.0 (2.0) 3.6 (2.5) 0.23 2.9 (1.3) 4.7 (2.3) 0.04*
Data are given as mean (SD). BMR indicates basal microcirculatory resistance; BP, blood pressure; bpm, beats per minute; CFR, coronary ﬂow reserve; FFR, fractional ﬂow reserve; GLP-1,
glucagon-like peptide-1; IMR, index of microcirculatory resistance; Pa, aortic pressure; Pd, distal coronary pressure; RRR, resistance reserve ratio; Tmn, transit time.
*P=0.04 for baseline nonhyperemic Tmn intergroup comparison.
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control arm of the PCI study, but other demographic data
were similar. In particular, all patients were taking a statin. All
patients received drug-eluting stents, and these were a similar
size with a similar total ischemic time to the cardiac
myocardium, as measured by the total coronary balloon
occlusion time.
Figure 5. Comparison of resting transit time (Tmn) and basal microcirculatory resistance (BMR) at baseline and after 20-minute
infusion of GLP-1 (glucagon-like peptide-1) (n=10, A and C) or saline control (n=11, B and D) before hyperemia. Both Tmn and BMR
decrease after GLP-1, whereas after saline, they both increase, suggesting GLP-1 is a coronary microvascular vasodilator. Changes in
resting Tmn (E) and BMR (F) after GLP-1 or saline controls at 20 minutes after percutaneous coronary intervention compared with
baseline accentuate this difference.
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Forearm Blood Flow
Blood pressure and heart rate during the forearm GLP-1
infusions remained constant (Figures 2 and 3). There was no
effect of GLP-1 on absolute blood ﬂow in the control (P=0.17)
or infused (P=0.77) forearms, forearm blood ﬂow ratio
(P=0.19), or percentage change in forearm blood ﬂow ratio
(P=0.20) from baseline or any of the 5 incremental doses of
GLP-1 (Figure 4). There were no hypoglycemic episodes
conﬁrmed by intermittent ﬁnger-prick glucometer readings.
Coronary Blood Flow
The changes in mean hemodynamic indexes after PCI at
baseline and after 20 minutes of GLP-1 or saline control are
summarized in Table 2. GLP-1 had no effect on resting heart
rate, systolic or diastolic blood pressure, or mean arterial
pressure; there was no change in resting coronary pressure
indexes (Table 2). However, GLP-1 did cause a signiﬁcant
reduction in resting Tmn (P=0.02), as exempliﬁed in Figure 1,
reﬂecting an increase in coronary ﬂow velocity that drove
down BMR compared with baseline resting values (P=0.02,
Figure 5). In saline-infused controls, the Tmn and BMR did the
opposite and increased 20 minutes after stenting compared
with baseline (P<0.001 and P=0.02 respectively; Table 2 and
Figure 5). This reduction in coronary ﬂow velocity increased
the CFR and resistance reserve ratio in the control group,
although there was no signiﬁcant inﬂuence of saline or GLP-1
on hyperemic pressure or ﬂow velocity indexes. The apparent
increase in CFR and resistance reserve ratio after saline was
driven by a deterioration basal ﬂow velocity and increase of
BMR, leading to an increase in the ratios observed.
When comparing GLP-1 and saline effect between patient
groups, the highly signiﬁcant and opposite difference in
resting Tmn response after GLP-1 and saline (P<0.001,
Figure 5) was responsible for the difference in change in
BMR (P<0.001).
Biochemistry
Biochemical data are summarized in Table 3. GLP-1 (7–36)
NH2 and its metabolite (9–36) NH2 both increased, as
expected, after a 20-minute infusion, but GLP-1 had no
signiﬁcant effect on blood glucose, free fatty acid, or insulin
concentrations. Simultaneous blood samples taken from the
coronary sinus and coronary artery reveal a modest, but
signiﬁcant, transmyocardial extraction of GLP-1 (7–36)
(P=0.03) but not GLP-1 (9–36) (P=0.09) (Figure 6).
There was no signiﬁcant transmyocardial uptake of glucose
(0.13 mmol/L, P=0.1), free fatty acid (8.9 lmol/L, P=0.26),
or insulin (0.13 pmol/L, P=0.8) during GLP-1 infusion.
Table 3. Peripheral Venous Plasma Biochemistry Results at
Baseline and After GLP-1 Administration for 20 Minutes
Variable Baseline GLP-1 P Value
Blood glucose, mmol/L 6.4 (1.7) 5.9 (1.2) 0.15
Free fatty acid, lmol/L 1326 (600.5) 1157 (600.5) 0.14
Insulin, pmol/L 68.44 (68.4) 60.7 (47.6) 0.20
GLP-1 (7–36), pmol/L 1.3 (1.9) 16.2 (7.7) <0.001
GLP-1 (9–36), mol/L 6.8 (3.2) 46.7 (14.4) <0.0001
Data are given as mean (SD). GLP-1 indicates glucagon-like peptide-1.
Figure 6. Transmyocardial extraction of GLP-1 (glucagon-like
peptide-1 [7–36] and GLP-1 [9–36]) calculated by simultaneously
collected blood sample analysis from coronary artery (CA) and
coronary sinus (CS); n=10.
Table 4. GLP-1 Localization by Tissue Type Using
Immunohistochemistry With mAb 3F52
Tissue GLP-1R–Expressing Cells
Intensity of
GLP-1R Staining
Pancreas b cells
Acinar cells
+++
+
Atria Cardiomyocytes ++
Ventricle Cardiomyocytes ++
Aorta No staining
Coronary artery No staining
Radial artery No staining
Left internal
mammary artery
No staining
Saphenous vein No staining
GLP-1 indicates glucagon-like peptide-1; GLP-1R, GLP-1 receptor; mAb, monoclonal
antibody; +, low; ++, medium; +++, high.
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Immunohistochemistry
The tissue-speciﬁc localization of GLP-1R observed with the
mAb 3F52 antibody is summarized in Table 4. As expected,
the pancreas had weak staining in acinar cells and high
staining in b cells, as illustrated in Figure 7A and 7B), and we
conﬁrmed no staining in pancreatic and atrial tissue without
the antibody in negative controls (Figures 7C and 7F). Atrial
and ventricular tissue both showed moderate staining of GLP-
1R in cardiomyocytes, with no apparent localization to any
region (Figure 7D, 7E, 7G, and 7H). Coronary microvessels
were visible in both atria and ventricle tissue (Figure 7E and
7H), although no staining with the GLP-1R mAb was observed
on the vascular endothelium or smooth muscle cells.
Figure 8 illustrates that there was also no staining in any
vascular specimen examined (aorta, left internal mammary
artery, coronary artery, saphenous vein, or radial artery).
Two presumably immune cells were visible with moderate
staining in the adventitia of the left internal mammary artery
section, indicating that the antibody assay had worked
(Figure 8E).
Discussion
We have clearly demonstrated that GLP-1 (7–36) NH2 has no
peripheral forearm vasodilatory effect and that the GLP-1R is
not expressed in peripheral or coronary vascular endothe-
lium or smooth muscle cells. However, GLP-1 is a coronary
microcirculatory vasodilator and is likely to bind to GLP-1Rs
on cardiomyocytes, as indicated by transmyocardial GLP-1
A B
C D
Figure 7. Immunohistochemistry sections labelling the glucagon-like peptide-1 receptor (GLP-1R) with and
without monoclonal antibody (mAb) 3F52. A, Pancreatic tissue, low power (magniﬁcation 920), positive control
with mAb 3F52, showing moderate widespread staining for GLP-1R and high staining for GLP-1R in b cells.
B, Pancreatic tissue, positive control with mAb 3F52, high power (magniﬁcation 960), boxed area of A. C,
Pancreatic tissue, negative control without mAb 3F52, high power (magniﬁcation 960), conﬁrming no staining.
D, Atrial tissue with mAb 3F52, low power (magniﬁcation 920), showing moderate widespread staining for GLP-1R
in atrial cardiomyocytes. E, Atrial tissue, with mAb 3F52, high power (magniﬁcation 960), boxed area of D, showing
staining of cardiomyocytes but no staining in the endothelial cells of a coronary vessel (arrow). F, Atrial tissue,
negative control without mAb 3F52, high power (magniﬁcation 960), without staining. G, Ventricular tissue with
mAb 3F52, low power (magniﬁcation 920), showing moderate widespread staining for GLP-1R in ventricular
cardiomyocytes. H, Ventricular tissue with mAb 3F52, high power (magniﬁcation 960), boxed area of G, showing
moderate widespread staining for GLP-1R in cardiomyocytes but no staining on the endothelial cells of a coronary
vessel (arrow).
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(7–36) NH2 extraction and GLP-1R staining on ventricular
cardiomyocytes. There was no signiﬁcant change in
metabolic substrate proﬁle after GLP-1. This suggests that
GLP-1 has a direct action on cardiomyocytes and inﬂuences
coronary microvascular ﬂow and resistance indirectly
through ventricular-coronary interactions. We also conﬁrm
that coronary ﬂow velocity diminishes with time after PCI in
the control group.
GLP-1 agonists have been shown to have beneﬁcial cardio-
vascular effects in patients with diabetes mellitus.7 We have
previously shown that GLP-1 can abrogate ischemic left
ventricular (LV) dysfunction in a human angioplasty model of
stunning.12,13,33 Although peripheral hemodynamic effects
have been described in animals,18–20 the ventricular effects of
GLP-1 (7–36) are not explained in humans by peripheral
vasodilatation and a reduction in afterload. We could not
visualize the presence of the GLP-1R in vascular tissue, and
forearm blood ﬂow measurements remained constant despite
incremental GLP-1 infusion doses. Systemic blood pressure and
pulse rate also remained constant in both the coronary and
forearm blood ﬂow studies during GLP-1 infusion.
However, we did observe coronary vasodilatation with
enhanced coronary ﬂow velocity during GLP-1 (7–36), and this
is compatible with the observed augmentation of LV function
during ischemia after GLP-1 through a mechanism of ventric-
ular-coronary cross talk. Coronary perfusion and contractility
are linked by several factors to match supply and demand.
Physical forces from increased inotropy and matched
lusitropy are thought to “pull open” the adjacent microvas-
culature, increasing coronary microcirculatory volume and
reducing resistance.34 We have previously shown that the
coronary backward expansion wave is proportional to LV
diastolic indexes measured by conductance catheter.35
Improved lusitropy also diminishes the compressive forces
of end diastolic pressure and wall stress acting on the
subendocardial microvasculature from the LV cavity.
Microvascular dilatation can, in turn, promote contractility
by stretching adjacent ventricular myoﬁbrils and activating
stretch-activated calcium channels in cardiomyocytes to
augment contraction by the Gregg effect.
Whether GLP-1 acts directly or indirectly on the ventricular
myocardium depends on where its receptor is expressed. We
conﬁrmed myocardial extraction of GLP-1, and our immuno-
histochemistry data suggest that GLP-1 may bind to receptors
on ventricular myocytes and promote contractility directly,
with secondary vasodilatory effects on the coronary micro-
circulation. However, other groups have shown with immuno-
histochemistry and gene expression studies that the GLP-1R
E F
G H
Figure 7. Continued.
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C D
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G H
Figure 8. Immunohistochemistry sections labelling glucagon-like peptide-1 receptor (GLP-1R) with
monoclonal antibody (mAb) 3F52 in human blood vessels. None show positive staining for the GLP-1R.
A, Coronary artery, low power (magniﬁcation 920). B, Coronary artery, high power (magniﬁcation 960).
C, Aorta, high power (magniﬁcation 960). D, Left internal mammary artery, high power (magniﬁcation 960).
E, Adventitia of left internal mammary artery, high power (magniﬁcation 960), which includes 2 presumably
immune cells with positive staining for GLP-1R (arrows). F, Saphenous vein, high power (magniﬁcation 960).
G, Radial artery, low power (magniﬁcation 920). H, Radial artery, high power (magniﬁcation 960), boxed area
of G.
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is localized to vascular smooth muscle and sinoatrial tissue
rather than ventricular tissue.16,17 If this is the case, our
ﬁndings could be explained by the Gregg effect. However, a
recent study of GLP-1R expression in the human heart
showed similar results to those presented herein and
identiﬁed a low-level expression in all 4 heart chambers,
although the expression could not be localized to a speciﬁc
cell type.36 Furthermore, this study did not detect any GLP-1R
expression in coronary artery vascular smooth muscle cells,
which corroborate our observations. A metabolic effect of
GLP-1 on the heart, switching from free fatty acid use to more
energy-efﬁcient glucose metabolism,37 seems unlikely,
because we did not observe any changes in plasma substrate
availability after GLP-1.
The observation that coronary ﬂow velocity diminishes with
time after PCI has been reported before by our group and may
be explained by the gradual dissipation of reactive hyperemia
and ischemia induced by repeated coronary balloon inﬂations
during PCI.38 The degree of reactive hyperemia is likely to be
similar between GLP-1–treated and saline controls because
the total ischemic time was similar; although the augmented
coronary ﬂow velocity wanes with time in controls, as
expected, it is further increased after GLP-1. Indexes may
be inﬂuenced by changes in basal ﬂow (eg, CFR should be
used with caution to gauge the interventional result), because
basal ﬂow is not stable after PCI. In addition, the observed
increase in CFR and resistance reserve ratio with time after
PCI in the control group must also be interpreted with caution;
it does not reﬂect improved hyperemic response in coronary
ﬂow velocity, but rather a reduction in resting ﬂow.
Clinical Signiﬁcance
Our ﬁndings are clinically important for patients with type 2
diabetes mellitus. GLP-1–based therapies can be used to
improve glycemic control and appear to be associated with
either a neutral or even improved cardiovascular proﬁle, unlike
some other agents.39 A nonglycemic coronary vasodilatory
effect in patients with diabetes mellitus and particularly at risk
of morbidity from coronary microvascular dysfunction is
desirable. However, we conﬁrm that GLP-1 administration in a
nondiabetic population is also safe and may encourage a
wider application of this therapy to treat coronary microvas-
cular dysfunction. Our data provide compelling justiﬁcation to
further evaluate the use of GLP-1 in larger studies to improve
myocardial blood ﬂow.
Limitations
We did not use a positive control (eg, sodium nitroprusside) in
the forearm blood ﬂow experiments to conﬁrm an endothelium-
independent vasodilatory effect could be detected with this
technique, although this has been shown before.27 We also only
assessed the direct vasodilatory potential of GLP-1 and not its
ability to augment the vasodilatory response of other agents, as
has been demonstrated by others.40 Baseline coronary artery
ﬂow may be perturbed by external factors, but ambient
temperature was constant and noise and discomfort were
minimal during data acquisition. We accept that basal ﬂow
velocity is variable, and the response to GLP-1 will depend on
basal coronary ﬂow. An effect of GLP-1 may only be
observed in individuals with abnormal basal ﬂow, as is
frequently encountered in patients with diabetes mellitus,
although conﬁrmation of our ﬁndings in this patient group is
warranted. The subtle GLP-1 coronary vasodilatory effect can
be swamped by exogenous vasodilators (eg, adenosine).
Hyperemic indexes are usually used clinically to determine
coronary microvascular integrity to overcome limitations of
basal ﬂow variability; however, they are artiﬁcial, pharmaco-
logically induced readings that are not steady state and, as
we have observed, may be misleading if basal ﬂow conditions
are ignored.
We did not assess the LV function before recruitment, and
we did not assess it intraprocedurally, to conﬁrm our previous
ﬁndings of abrogation of ischemic LV dysfunction and
stunning after GLP-1. This was also not a randomized
controlled trial, but rather patients acted as their own control,
and as such, investigators were not blinded to treatment
allocation.
This was a human study and, therefore, our physiological
and histopathological data could not be gathered from the
same subject. However, the myocardial extraction data,
paired with our histopathological data conﬁrming GLP-1R
presence on ventricular tissue, are persuasive. Although we
used a well-characterized mAb 3F52 speciﬁc to the GLP-1R,
we did not conﬁrm the presence of the GLP-1R with another
method, and it is possible an alternative tissue binding
pattern and mechanism may be responsible for our obser-
vations. For example, GLP-1 and its metabolite have been
demonstrated to act independently of the GLP-1R in a rodent
model,41 and this may also be the case in humans. Finally,
we also did not deﬁnitively conﬁrm GLP-1 binding; degrada-
tion could also explain the transmyocardial gradient we
observed.
Conclusion
GLP-1 causes coronary microvascular dilation but does not
inﬂuence peripheral vascular tone. GLP-1Rs are expressed on
ventricular cardiomyocytes but not vascular tissue, and
transmyocardial GLP-1 extraction occurs, suggesting that
the GLP-1 effect on the coronary microvasculature is
indirectly mediated by ventricular-coronary cross talk.
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